AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06627088
Drug: [14C]-LY4100511 (DC-853) Administered oral dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered oral dose
Trial: NCT06627088
Drug: [14C]-LY4100511 (DC-853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV infusion
Trial: NCT05677451
Drug: LOU064 (blinded)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOU064 (blinded) active treatment
Trial: NCT05677451
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching active drug
Trial: NCT04528082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the matching placebo orally.
Trial: NCT05895825
Drug: EOC237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOC237 for orally
Trial: NCT06685068
Drug: GEN1286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06326463
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -3 and Day-2~REST DAY, -1
Trial: NCT05645276
Drug: AK129 IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
Trial: NCT06695026
Drug: RZ-001 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
Trial: NCT06695026
Drug: RZ-001 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
Trial: NCT06695026
Drug: RZ-001 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
Trial: NCT06629779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous
Trial: NCT04894474
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous
Trial: NCT04894474
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation
Trial: NCT05695859
Drug: 99mTc-DARPinG3 SPECT/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
Trial: NCT06687070
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected on the first day of each cycle, every 28 days as a cycle.
Trial: NCT04803786
Drug: Transition from Xyrem to Xywav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
Trial: NCT05202366
Drug: CGB-400 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
Trial: NCT05590234
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of normal saline 0.9%.
Trial: NCT04997837
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Trial: NCT04997837
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
Trial: NCT06004830
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
Trial: NCT04567420
Drug: Adjuvant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT05827146
Drug: Hepalatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Trial: NCT05827146
Drug: Hepalatide Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Trial: NCT04539808
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04539808
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04539808
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04611529
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400mg
Trial: NCT04611529
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 1% gel 4gm
Trial: NCT06709014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule by mouth once daily for 18 months
Trial: NCT04772365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be subcutaneously administered with different dose levels;
Trial: NCT06627322
Drug: Triple-combination therapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
Trial: NCT06453447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
Trial: NCT05908383
Drug: GMDTC for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Trial: NCT06192446
Drug: Survey using a questionnaire.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An observational study conducted in a cross-sectional manner using a questionnaire.
Trial: NCT05463679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
Trial: NCT05097976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 sugar tablets beginning on POD 1 with standard management
Trial: NCT06650761
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 3 infusions of Normal Saline
Trial: NCT04795596
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: second line chemotherapy according to investigator's choice
Trial: NCT06361277
Drug: Reference Drug or Test Drug
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
Trial: NCT05430230
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen tablets
Trial: NCT06554626
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: antifolate antineoplastic drug
Trial: NCT05427682
Drug: pyroglutamate rongliflozin capsules
RxNorm normalized name: pyroglutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one 50mg capsule on Day 1
Trial: NCT06265532
Drug: Placebo for EGCG 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect.
Trial: NCT06265532
Drug: Placebo for EGCG 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect.
Trial: NCT05975073
Drug: IDE397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered PO
Trial: NCT05542303
Drug: ZB001 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Cohort1 (3mg/kg) ZB001 of single IV injection
Trial: NCT05542303
Drug: ZB001 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Cohort2 (10mg/kg) ZB001 of single IV injection
Trial: NCT05542303
Drug: ZB001 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Cohort3 (20mg/kg) ZB001 of single IV injection
Trial: NCT05536726
Drug: 608 Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
Trial: NCT05536726
Drug: 608 Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
Trial: NCT05536726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Trial: NCT06705998
Drug: BAR502 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg).
Trial: NCT06705998
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Trial: NCT06705998
Drug: BAR502 multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.
Trial: NCT06512818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
Trial: NCT06712316
Drug: BNT327
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06707142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT04539041
Drug: antisense oligonucleotide
RxNorm normalized name: Antisense oligonucleotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
Trial: NCT04539041
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for each dose level
Trial: NCT06687967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Trial: NCT06694714
Drug: 0.5 ml lidocaine + epinephrine 1:100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
Trial: NCT06694714
Drug: 1.0 ml lidocaine + epinephrine 1:100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
Trial: NCT04794699
Drug: IDE397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDE397 dosed orally
Trial: NCT06712836
Drug: MET097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
Trial: NCT06715540
Drug: BCD-261, dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Trial: NCT06715540
Drug: BCD-261, dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Trial: NCT06715540
Drug: BCD-261, dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Trial: NCT06715540
Drug: BCD-261, pre-specified therapeautic dose X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Trial: NCT06715540
Drug: BCD-261, pre-specified therapeautic dose X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Trial: NCT06715540
Drug: BCD-261, pre-specified therapeautic dose Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Trial: NCT06677957
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
Trial: NCT06705088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A look-alike tablet with no active ingredient.
Trial: NCT04750616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo on the day of surgery and post-surgical days one and two
Trial: NCT05632133
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
Trial: NCT05359263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparator arm consists of placebo orally once daily
Trial: NCT05033444
Drug: PRV-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated.
Trial: NCT05033444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
Trial: NCT06045624
Drug: OR-101 (Single ascending dose)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
Trial: NCT06045624
Drug: OR-101 (Food effect)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
Trial: NCT05646797
Drug: ASP2074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) infusion
Trial: NCT06045624
Drug: OR-101 (Multiple ascending dose)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
Trial: NCT06045624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo across Part A and C of the study
Trial: NCT04935879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
Trial: NCT05783180
Drug: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
Trial: NCT05783180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
Trial: NCT06716645
Drug: Robitussin Maximum Strength Cough and Chest Congestion DM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg
Trial: NCT06716645
Drug: Robitussin Maximum Strength Cough and Chest Congestion DM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg
Trial: NCT06719011
Drug: NNC0174-1213 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Trial: NCT06718686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug
Trial: NCT06717698
Drug: NNC0519-0130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0519-0130 will be administered subcutaneously.
Trial: NCT06717698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching NNC0519-0130 will be administered subcutaneously.
Trial: NCT06421415
Drug: Allergen Immunotherapy Extract
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated as usual. The study is an observation of the long term effect of the treatment
Trial: NCT06500273
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy for lymphodepletion
Trial: NCT06723626
Drug: Metabolic resuscitation agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).
Trial: NCT06723626
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo group will receive intravenous hydrocortisone 200mg every 24 hours.
Trial: NCT06722430
Drug: Icalcaprant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05578456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2 starch tablets per day per os
Trial: NCT05243550
Drug: UGN-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Trial: NCT06168708
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)